I agree that this site is using cookies. You can find further informations here.
X
Banerjee, Subhashis
318  results:
Search for persons X
?
1

Plain Language Summary of the PAISLEY study: deucravacitini..:

Morand, Eric F. ; Pike, Marilyn ; Merrill, J...
Expert Opinion on Investigational Drugs.  33 (2024)  5 - p. 431-440 , 2024
Link: https://doi.org/10.1080/..
 
?
2

Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inh..:

Gottlieb, Alice B. ; Armstrong, April W. ; Merola, Joseph F....
SKIN The Journal of Cutaneous Medicine.  8 (2024)  2 - p. s383 , 2024
Link: https://doi.org/10.25251..
 
?
3

Deucravacitinib in Moderate Plaque Psoriasis: Efficacy in t..:

Blauvelt, Andrew ; Korman, Neil J. ; Merola, Joseph F....
SKIN The Journal of Cutaneous Medicine.  8 (2024)  2 - p. s364 , 2024
Link: https://doi.org/10.25251..
 
?
4

Deucravacitinib, a selective, allosteric tyrosine kinase 2 ..:

Blauvelt, Andrew ; Rich, Phoebe ; Sofen, Howard...
Journal of the American Academy of Dermatology.  90 (2024)  4 - p. 775-782 , 2024
Link: https://doi.org/10.1016/..
 
?
5

Traceable mixnets:

Agrawal, Prashant ; Nakarmi, Abhinav ; Jhanwar, Mahabir Prasad..
Proceedings on Privacy Enhancing Technologies.  2024 (2024)  2 - p. 235-275 , 2024
Link: https://doi.org/10.56553..
 
?
6

Deucravacitinib onset of action and maintenance of response..:

Korman, Neil J. ; Warren, Richard B. ; Bagel, Jerry...
Journal of Dermatological Treatment.  35 (2024)  1 - p. , 2024
Link: https://doi.org/10.1080/..
 
?
7

Streamlining neuroradiology workflow with AI for improved c..:

Banerjee, Subhashis ; Nysjö, Fredrik ; Toumpanakis, Dimitrios...
Scientific Reports.  14 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
8

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Ki..:

Alexis, Andrew F. ; Merola, Joseph F. ; Zhong, Yichen...
SKIN The Journal of Cutaneous Medicine.  8 (2024)  2 - p. s358 , 2024
Link: https://doi.org/10.25251..
 
?
9

Deucravacitinib in plaque psoriasis: 2-year safety and effi..:

Lebwohl, Mark ; Warren, Richard B ; Sofen, Howard...
British Journal of Dermatology.  190 (2024)  5 - p. 668-679 , 2024
Link: https://doi.org/10.1093/..
 
?
10

P096 Deucravacitinib, an oral, selective, allosteric tyrosi..:

Kearney, Niamh ; Pink, Andrew ; Hoyt, Kim...
British Journal of Dermatology.  191 (2024)  Supplement_1 - p. i60-i61 , 2024
Link: https://doi.org/10.1093/..
 
?
11

Deucravacitinib Long-Term Efficacy in Week 16 Placebo Cross..:

Lebwohl, Mark ; Warren, Richard B. ; Imafuku, Shinichi...
SKIN The Journal of Cutaneous Medicine.  8 (2024)  2 - p. s365 , 2024
Link: https://doi.org/10.25251..
 
?
12

Deucravacitinib in Plaque Psoriasis: 3-year Safety and Effi..:

Armstrong, April W. ; Lebwohl, Mark ; Warren, Richard B....
SKIN The Journal of Cutaneous Medicine.  8 (2024)  2 - p. s366 , 2024
Link: https://doi.org/10.25251..
 
?
13

Deucravacitinib, an oral, selective, allosteric tyrosine ki..:

Imafuku, Shinichi ; Okubo, Yukari ; Tada, Yayoi...
The Journal of Dermatology.  51 (2024)  3 - p. 365-379 , 2024
Link: https://doi.org/10.1111/..
 
?
14

Biochemical, Biomarker, and Behavioral Characterization of ..:

Smith, Denise M. ; Aggarwal, Geetika ; Niehoff, Michael L....
Molecular Neurobiology.  , 2024
Link: https://doi.org/10.1007/..
 
?
15

Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Bi..:

FitzGerald, Oliver ; Gladman, Dafna D. ; Mease, Philip J....
Arthritis & Rheumatology.  , 2024
Link: https://doi.org/10.1002/..
 
1-15